Clarivate Shares Drop 4.9% as Revenue Miss Widens Analyst Divide

Clarivate PLC (NYSE:CLVT) fell 4.9% in mid-day trading on Monday, trading as low as $2.20 and last changing hands at $2.2250, down from a prior close of $2.34. Only 429,116 shares traded — a 93% decline from the average session volume of 5,995,883 shares.

The move caps a bruising stretch for the analytics and intellectual-property information provider, whose shares now sit near their 200-day moving average of $2.20 and above the 50-day average of $1.84.

What did the last earnings report show?

The company posted quarterly results on Wednesday, November 4th. Earnings per share came in at $0.21, beating the consensus estimate of $0.18 by $0.03. Revenue told a harder story: $481.60 million for the quarter against a consensus of $566.77 million, a shortfall of more than $85 million.

Revenue fell 22.7% compared with the same quarter last year. In that prior-year quarter, the firm posted $0.18 EPS. Clarivate recorded a negative net margin of 17.02% alongside a positive return on equity of 9.84%. Sell-side analysts, as a group, expect the company to post $0.64 EPS for the current year.

The takeaway: profits beat, but a double-digit revenue contraction set the tone for the analyst community.

How are analysts responding?

Research firms have spent months trimming their outlooks on CLVT:

• Barclays cut its price objective from $2.50 to $2.00 and set an "underweight" rating on Thursday, July 30th.
• The Goldman Sachs Group reduced its target from $2.60 to $2.30 with a "neutral" rating on Thursday, November 5th.
• Wall Street Zen downgraded the stock from "buy" to "hold" on Saturday, August 1st.
• Weiss Ratings restated a "sell (e+)" rating on Monday, September 21st.
• William Blair downgraded Clarivate to "market perform" on Thursday, October 15th.

One investment analyst rates the stock Buy, five assign Hold and three assign Sell. Per MarketBeat data, the stock carries an average rating of "Reduce" and an average price target of $2.65 — above the last traded price, but an average pulled down by successive cuts through the year.

What does the balance sheet look like?

Clarivate carries a market capitalization of $1.52 billion. The stock trades at a P/E ratio of -3.89, reflecting the company's negative earnings, with a beta of 1.38.

Liquidity metrics show a quick ratio of 0.88 and a current ratio of 0.88. The debt-to-equity ratio stands at 0.92.

How are institutional investors positioned?

Several hedge funds adjusted their stakes in recent quarters:

• Parallel Advisors LLC raised its holdings 94.2% in the first quarter, adding 6,687 shares to own 13,786 shares valued at $35,000.
• Royal Bank of Canada lifted its position 44.8% in the first quarter, buying 10,149 additional shares to hold 32,818 shares worth $83,000.
• Ancora Advisors LLC boosted its stake 12.3% in the second quarter, acquiring 10,970 shares to reach 100,000 shares valued at $216,000.
• FreeGulliver LLC bought a new stake in the first quarter valued at $30,000.
• Vise Technologies Inc. increased its holdings 50.4% in the third quarter, adding 12,512 shares to own 37,327 shares valued at $62,000.

Hedge funds and other institutional investors own 85.72% of the company's stock, meaning Monday's thin-volume decline moved prices with relatively few shares changing hands.

What does Clarivate actually do?

The company provides information, analytics and workflow tools to customers in academia and government, life sciences and healthcare, and intellectual property. Its services help organizations find and analyze research, assess scientific and commercial developments, and manage patents, trademarks and other intellectual property. Its products include Web of Science and ProQuest research resources, Cortellis life sciences intelligence, and intellectual property databases and services such as Derwent.

The plain summary: a 4.9% price drop on 93% below-average volume, a 22.7% revenue decline, and a consensus "Reduce" rating together sketch a company whose valuation now rests on stabilization rather than growth.